Please use this identifier to cite or link to this item:
Title: Clinical Management of COVID-19 in Cancer Patients with the STAT3 Inhibitor Silibinin
Author: Bosch Barrera, Joaquim
Roqué, Ariadna
Teixidor, Eduard
Carmona Garcia, Maria Carmen
Arbusà, Aina
Brunet, Joan
Martin Castillo, Begoña
Cuyàs, Elisabet
Verdura, Sara
Menendez, Javier A.
Keywords: COVID-19
Medicina clínica
Malalts de càncer
Clinical medicine
Cancer patients
Issue Date: 24-Dec-2021
Publisher: MDPI AG
Abstract: COVID-19 pathophysiology is caused by a cascade of respiratory and multiorgan failures arising, at least in part, from the SARS-CoV-2-driven dysregulation of the master transcriptional factor STAT3. Pharmacological correction of STAT3 over-stimulation, which is at the root of acute respiratory distress syndrome (ARDS) and coagulopathy/thrombosis events, should be considered for treatment of severe COVID-19. In this perspective, we first review the current body of knowledge on the role of STAT3 in the pathogenesis of severe COVID-19. We then exemplify the potential clinical value of treating COVID-19 disease with STAT3 inhibitors by presenting the outcomes of two hospitalized patients with active cancer and COVID-19 receiving oral Legalon(R)-a nutraceutical containing the naturally occurring STAT3 inhibitor silibinin. Both patients, which were recruited to the clinical trial SIL-COVID19 (EudraCT number: 2020-001794-77) had SARS-CoV-2 bilateral interstitial pneumonia and a high COVID-GRAM score, and showed systemic proinflammatory responses in terms of lymphocytopenia and hypoalbuminemia. Both patients were predicted to be at high risk of critical COVID-19 illness in terms of intensive care unit admission, invasive ventilation, or death. In addition to physician's choice of best available therapy or supportive care, patients received 1050 mg/day Legalon(R) for 10 days without side-effects. Silibinin-treated cancer/COVID-19+ patients required only minimal oxygen support (2-4 L/min) during the episode, exhibited a sharp decline of the STAT3-regulated C-reactive protein, and demonstrated complete resolution of the pulmonary lesions. These findings might inspire future research to advance our knowledge and improve silibinin-based clinical interventions aimed to target STAT3-driven COVID-19 pathophysiology.
Note: Reproducció del document publicat a:
It is part of: Pharmaceuticals, 2021, vol. 15, num. 1, p. 19
Related resource:
Appears in Collections:Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL))

Files in This Item:
File Description SizeFormat 
pharmaceuticals-15-00019.pdf2.88 MBAdobe PDFView/Open

This item is licensed under a Creative Commons License Creative Commons